The current role of amphotericin B lipid complex in managing systemic fungal infections

References

• Enoch DA, Ludlam HA, Brown NM Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006;55:809-18
   PubMed Web of Science ®Google Scholar
• Barnes RA Early diagnosis of fungal infection in immunocompromised patients. J Antimicrob Chemother 2008;61(Suppl. 1):i3-i6
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004;42:4419-31
   PubMed Web of Science ®Google Scholar
• Linden P, Williams P, Chan KM Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplantation 2000;14:329-39
   PubMed Web of Science ®Google Scholar
• Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002;49(Suppl. S1):31-6
   PubMedGoogle Scholar
• Lanternier F, Lortholary O. Liposomal amphotericin B: what is its role in 2008?. Clin Microbiol Infect 2008;14(Suppl. 4):71-83
   PubMedGoogle Scholar
• Morris MI, Villman M. Echinocandins in the management of invasive fungal infections, part 2. Am J Health-Syst Pharm 2006;63:1813-20
   PubMed Web of Science ®Google Scholar
• Knapp KM, Flynn PM Newer treatments for fungal infections. J Support Oncol 2005;3:290-8
   PubMedGoogle Scholar
• Maschmeyer G. New antifungal agents – treatment standards are beginning to grow old. J Antimicrob Chemother 2002;49:239-41
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39:425-9
   PubMed Web of Science ®Google Scholar
• Girmenia C, Moleti ML, Micozzi A, et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 2005;43:5395-6
   PubMed Web of Science ®Google Scholar
• Myoken Y, Kyo T, Sugata T, et al. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. Haematologica 2006;91:287-8
   PubMed Web of Science ®Google Scholar
• Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007;30:551-4
   PubMed Web of Science ®Google Scholar
• Jamieson C. Fungal infections – pharmacological therapy. Hospital Pharmacist 2006;13:321-5
   Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96
   PubMed Web of Science ®Google Scholar
• Martino R. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004;20:485-504
   PubMed Web of Science ®Google Scholar
• Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21
   PubMed Web of Science ®Google Scholar
• Martino R, Subirá M, Domingo-Albós A, et al. Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia. Chemotherapy 1999;45:205-12
   PubMed Web of Science ®Google Scholar
• Linden P, Lee L, Walsh TJ Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Pharmacotherapy 1999;19:1261-8
   PubMed Web of Science ®Google Scholar
• Martino R, Subirá M, Sureda A, et al. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother 1999;44:569-72
   PubMed Web of Science ®Google Scholar
• Martino R, Cortés M, Subirá M, et al. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005;46:1429-35
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66
   PubMed Web of Science ®Google Scholar
• Subirà M, Martino R, Gómez L, et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial. Eur J Haematol 2004;72:342-7
   PubMed Web of Science ®Google Scholar
• Miller CB, Waller EK, Klingemann HG, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 2004;33:543-8
   PubMed Web of Science ®Google Scholar
• Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-320
   PubMed Web of Science ®Google Scholar
• Oravcová E, Mistrik M, Sakalová A, et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy 1995;41:473-6
   PubMed Web of Science ®Google Scholar
• Wingard JR Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997;19:343-7
   PubMed Web of Science ®Google Scholar
• Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997;20:39-43
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702-8
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Auvrignon A, Andrès E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001;20:77-82
   PubMed Web of Science ®Google Scholar
• Wiley JM, Seibel NL, Walsh TJ Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24:167-74
   PubMed Web of Science ®Google Scholar
• Clark AD, McKendrick S, Tansey PJ, et al. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 1998;103:198-204
   PubMed Web of Science ®Google Scholar
• Cannon JP, Garey KW, Danziger LH A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001;21:1107-14
   PubMed Web of Science ®Google Scholar
• Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al.; for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• Chamilos G, Kontoyiannis DP Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resistance Updates 2005;8:344-58
   PubMed Web of Science ®Google Scholar
• Hachem RY, Boktour MR, Hanna HA, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008;112:1282-7
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Aguado JM, Lumbreras C, González-Vidal D, et al. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. Clin Microbiol Infect 2004;10:785-90
   PubMed Web of Science ®Google Scholar
• Luke RG, Boyle JA Renal effects of amphotericin B lipid complex. Am J Kid Dis 1998;31:780-5
   PubMed Web of Science ®Google Scholar
• Alexander BD, Wingard JR Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40:S414-21
   PubMed Web of Science ®Google Scholar
• Tiphine M, Letscher-Bru V, Herbrect R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999;1:273-83
   PubMedGoogle Scholar
• O'Connor N, Borley A. Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex. Curr Med Res Opin 2009;25:749-54
   PubMed Web of Science ®Google Scholar
• Drew R, Ashley E, Benjamin D, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-37
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-8
   PubMed Web of Science ®Google Scholar
• Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006;6:2765-73
   PubMed Web of Science ®Google Scholar
• Flückiger U, Marchetti O, Bille J et al.; for the Fungal Infection Network of Switzerland (FUNGINOS).Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006;136:447-63
   PubMed Web of Science ®Google Scholar
• Kauffman CA Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006;9:1-6
   Web of Science ®Google Scholar
• Canuto MM, Rodero FG Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002;2:550-63
   PubMed Web of Science ®Google Scholar
• Dismukes WE Introduction to antifungal drugs. Clin Infect Dis 2000;30:653-7
   PubMed Web of Science ®Google Scholar
• Chen SCA, Sorrell TC Antifungal agents. MJA 2007;187:404-9
   PubMed Web of Science ®Google Scholar
• Khan ZU, Mokaddas EM Advances in therapy of invasive mycoses. Kuwait Med J 2007;39:98-106
   Google Scholar
• Ellis D. Amphoterin B: spectrum and resistance. J Antimicrobiol Chemother 2002;49(Suppl. S1):7-10
   PubMedGoogle Scholar
• Loeffler J, Stevens DA Antifungal drug resistance. Clin Infect Dis 2003;36(Suppl. 1):S31-41
   PubMed Web of Science ®Google Scholar
• Cowen LE, Steinbach WJ Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryotic Cell 2008;7:747-64
   PubMed Web of Science ®Google Scholar
• Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008;14(Suppl. 4):5-24
   PubMed Web of Science ®Google Scholar
• Garbino J, Schnetzler G, Roberts C. Invasive aspergillosis: is treatment with ‘inexpensive’ amphotericin B cost-saving if ‘expensive’ voriconazole is only used on demand?. Swiss Med Wkly 2005;135:624-30
   Google Scholar
• Kuti JL, Kotapati S, Williams P, et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004;22:301-10
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007;78:532-9
   PubMed Web of Science ®Google Scholar
• Collins CD, Stuntebeck ER, DePestel DD, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin Drug Invest 2007;27:233-41
   PubMed Web of Science ®Google Scholar
• Cornely O, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24:1743-53
   PubMed Web of Science ®Google Scholar
• Al-Badriyeh D, Liew D, Stewart K, et al. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chemother 2009;63:197-208
   PubMed Web of Science ®Google Scholar
• Tunger O, Bayram H, Degerli K, et al. Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. Saudi Med J 2008;29:728-33
   PubMed Web of Science ®Google Scholar
• Esposito V, Viglietti R, Gargiulo M, et al. Successful treatment of cryptococcal meningitis with a combination of amphotericin B, flucytosine and posaconazole: two case reports. In Vivo 2009;23:465-8
   PubMed Web of Science ®Google Scholar
• Sedlacek P, Vavra V, Masova I, et al. Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia. Mycoses 2009;52:276-9
   PubMed Web of Science ®Google Scholar